247 related articles for article (PubMed ID: 28107795)
1. Adherence to therapies in cystic fibrosis: a targeted literature review.
Narayanan S; Mainz JG; Gala S; Tabori H; Grossoehme D
Expert Rev Respir Med; 2017 Feb; 11(2):129-145. PubMed ID: 28107795
[TBL] [Abstract][Full Text] [Related]
2. Aerosolized agents for airway clearance in cystic fibrosis.
Southern KW; Clancy JP; Ranganathan S
Pediatr Pulmonol; 2019 Jun; 54(6):858-864. PubMed ID: 30884217
[TBL] [Abstract][Full Text] [Related]
3. Dornase alfa for cystic fibrosis.
Yang C; Chilvers M; Montgomery M; Nolan SJ
Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
[TBL] [Abstract][Full Text] [Related]
4. Trends in the use of routine therapies in cystic fibrosis: 1995-2005.
Konstan MW; VanDevanter DR; Rasouliyan L; Pasta DJ; Yegin A; Morgan WJ; Wagener JS; ;
Pediatr Pulmonol; 2010 Dec; 45(12):1167-72. PubMed ID: 20717935
[TBL] [Abstract][Full Text] [Related]
5. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.
Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F
J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933
[TBL] [Abstract][Full Text] [Related]
6. Investigating self-efficacy, disease knowledge and adherence to treatment in adolescents with cystic fibrosis.
Faint NR; Staton JM; Stick SM; Foster JM; Schultz A
J Paediatr Child Health; 2017 May; 53(5):488-493. PubMed ID: 28186386
[TBL] [Abstract][Full Text] [Related]
7. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol for cystic fibrosis.
Nolan SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
[TBL] [Abstract][Full Text] [Related]
9. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
10. Medical management of chronic rhinosinusitis in cystic fibrosis: a systematic review.
Liang J; Higgins T; Ishman SL; Boss EF; Benke JR; Lin SY
Laryngoscope; 2014 Jun; 124(6):1308-13. PubMed ID: 24338982
[TBL] [Abstract][Full Text] [Related]
11. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
12. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
[TBL] [Abstract][Full Text] [Related]
14. Update on new pulmonary therapies.
Retsch-Bogart GZ
Curr Opin Pulm Med; 2009 Nov; 15(6):604-10. PubMed ID: 19696677
[TBL] [Abstract][Full Text] [Related]
15. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.
Nasr SZ; Chou W; Villa KF; Chang E; Broder MS
J Med Econ; 2013; 16(6):801-8. PubMed ID: 23506540
[TBL] [Abstract][Full Text] [Related]
16. Impact of pharmacy services on cystic fibrosis medication adherence.
Zobell JT; Schwab E; Collingridge DS; Ball C; Nohavec R; Asfour F
Pediatr Pulmonol; 2017 Aug; 52(8):1006-1012. PubMed ID: 28608652
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
18. The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial.
Gold LS; Hansen RN; Mayer-Hamblett N; Nichols DP; Gifford AH; Kloster M; Goss CH; Kessler L
J Manag Care Spec Pharm; 2024 Jan; 30(1):26-33. PubMed ID: 38153868
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.
Abbott J; Gee L
Paediatr Drugs; 2003; 5(1):41-56. PubMed ID: 12513105
[TBL] [Abstract][Full Text] [Related]
20. Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis.
Kirkham HS; Staskon F; Hira N; McLane D; Kilgore KM; Parente A; Kim S; Sawicki GS
Pediatr Pulmonol; 2018 Jun; 53(6):720-727. PubMed ID: 29512893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
